Gilead's Newly Approved HIV Prevention Drug Poised To Add Billions To Future Sales
1. FDA approved Gilead's Yeztugo as the first twice-yearly PrEP option. 2. ≥99.9% HIV negative results from Yeztugo in Phase 3 trials. 3. Positive EMA recommendation could grant EU market exclusivity. 4. Needham upgraded Gilead's rating, predicting significant revenue growth from Yeztugo. 5. Yeztugo could generate up to $6.4 billion by 2035.